Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Research analysts at Oppenheimer Holdings decreased their FY2017 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued on Monday. Oppenheimer Holdings analyst M. Gilson now forecasts that the brokerage will post earnings per share of ($4.39) for the year, down from their previous forecast of ($4.00). Oppenheimer Holdings also issued estimates for Sarepta Therapeutics’ FY2018 earnings at ($2.86) EPS.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same quarter last year, the business posted ($0.87) EPS.

Several other research firms have also recently issued reports on SRPT. Royal Bank Of Canada reissued a “hold” rating and issued a $5.00 target price on shares of Sarepta Therapeutics in a research report on Friday, June 3rd. Vetr raised shares of Sarepta Therapeutics from a “strong sell” rating to a “buy” rating and set a $17.28 price target on the stock in a research report on Thursday, June 2nd. RBC Capital Markets raised shares of Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating in a research report on Monday. William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, June 27th. Finally, Needham & Company LLC lifted their price target on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, July 22nd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and an average price target of $51.01.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/oppenheimer-holdings-research-analysts-lower-earnings-estimates-for-sarepta-therapeutics-inc-srpt.html

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 0.86% on Wednesday, hitting $55.25. 6,671,164 shares of the stock traded hands. The firm’s 50-day moving average is $28.17 and its 200 day moving average is $21.37. Sarepta Therapeutics has a 12-month low of $8.00 and a 12-month high of $58.87. The firm’s market cap is $2.65 billion.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its position in shares of Sarepta Therapeutics by 5.5% in the second quarter. Vanguard Group Inc. now owns 3,105,816 shares of the company’s stock valued at $59,227,000 after buying an additional 161,790 shares during the period. State Street Corp increased its position in shares of Sarepta Therapeutics by 25.3% in the second quarter. State Street Corp now owns 3,092,427 shares of the company’s stock valued at $58,976,000 after buying an additional 625,051 shares during the period. BlackRock Fund Advisors increased its position in shares of Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock valued at $32,439,000 after buying an additional 36,371 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock valued at $20,865,000 after buying an additional 25,799 shares during the period. Finally, Franklin Resources Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at about $13,506,000. 72.09% of the stock is owned by institutional investors.

In other news, CEO Edward M. Md Kaye sold 24,557 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $30.00, for a total transaction of $736,710.00. Following the completion of the transaction, the chief executive officer now owns 76,983 shares of the company’s stock, valued at $2,309,490. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.90% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.

5 Day Chart for NASDAQ:SRPT

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.